» Articles » PMID: 31153556

Clinically Significant Prostate Cancer Detection on MRI: A Radiomic Shape Features Study

Overview
Journal Eur J Radiol
Specialty Radiology
Date 2019 Jun 3
PMID 31153556
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Prostate multiparametric MRI (mpMRI) is the imaging modality of choice for detecting clinically significant prostate cancer (csPCa). Among various parameters, lesion maximum diameter and volume are currently considered of value to increase diagnostic accuracy. Quantitative radiomics allows for the extraction of more advanced shape features. Our aim was to assess which shape features derived from MRI index lesions correlate with csPCa presence.

Materials And Methods: We retrospectively enrolled 75 consecutive subjects, who underwent mpMRI on a 3 T scanner, divided based on MRI index lesion Gleason Score in a csPCa group (GS > 3 + 4, n = 41) and a non-csPCa one (n = 34). Ten shape features were extracted both from axial T2-weighted and ADC maps images, after lesion tridimensional segmentation. Univariable and multivariable logistic analysis were used to evaluate the relationship between shape features and csPCa. Diagnostic performance was assessed measuring the area under the curve of the receiver operating characteristic (ROC) analysis. Diagnostic accuracy, sensitivity, and specificity were determined using the best cut-off on each ROC. A P value < 0.05 was considered statistically significant.

Results: Univariable analysis demonstrated that almost every shape feature was statistically significant between csPCa e non-csPCa groups. However, multivariable analysis revealed that the parameter defined as surface area to volume ratio (SAVR), especially when extracted from ADC maps is the strongest independent predictor of csPCa among tested shape features.

Conclusion: The radiomic shape feature SAVR, extracted from ADC maps after index lesion segmentation, appears as a promising tool for csPCa detection.

Citing Articles

Biparametric MRI-based radiomics for noninvastive discrimination of benign prostatic hyperplasia nodules (BPH) and prostate cancer nodules: a bio-centric retrospective cohort study.

Lu Y, Yuan R, Su Y, Liang Z, Huang H, Leng Q Sci Rep. 2025; 15(1):654.

PMID: 39753878 PMC: 11698716. DOI: 10.1038/s41598-024-84908-w.


Quantitative magnetic resonance imaging in prostate cancer: A review of current technology.

Dhiman A, Kumar V, Das C World J Radiol. 2024; 16(10):497-511.

PMID: 39494137 PMC: 11525833. DOI: 10.4329/wjr.v16.i10.497.


Morphological MRI features as prognostic indicators in brain metastases.

Ocana-Tienda B, Perez-Beteta J, Ortiz de Mendivil A, Asenjo B, Albillo D, Perez-Romasanta L Cancer Imaging. 2024; 24(1):111.

PMID: 39164779 PMC: 11334491. DOI: 10.1186/s40644-024-00753-0.


Radiomics approach to distinguish between benign and malignant soft tissue tumors on magnetic resonance imaging.

Xu L, Wang M, Qi L, Zou Y, Fei-Yun W, Sun X Eur J Radiol Open. 2024; 12:100555.

PMID: 38544918 PMC: 10966448. DOI: 10.1016/j.ejro.2024.100555.


High-grade prostate cancer demonstrates preferential growth in the cranio-caudal axis and provides discrimination of disease grade in an MRI parametric model.

Mukherjee S, Papadopoulos D, Chari N, Ellis D, Charitopoulos K, Charitopoulos I Br J Radiol. 2024; 97(1155):574-582.

PMID: 38276882 PMC: 11027337. DOI: 10.1093/bjr/tqad066.